BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.








